PAI Life Sciences

PAI Life Sciences is a private, clinical-stage biotech with a dual mission: serving as a key supplier of research adjuvants and developing a proprietary pipeline targeting neglected tropical diseases (NTDs). Its core strategy is 'Serving the Underserved,' addressing diseases overlooked by larger pharmaceutical companies. The company has advanced its lead schistosomiasis vaccine candidate into human clinical trials (Phase 1 initiated in May 2022) and maintains a broader pipeline including programs for lymphatic filariasis, tuberculosis, and onchocerciasis. While currently pre-revenue from its therapeutic pipeline, it generates early revenue through its adjuvant supply business.

Adjuvant formulation and protein biotherapeutics platform for vaccine and therapeutic development.

In NTD vaccine development, PAI competes with non-profit product development partnerships (PDPs) like the Sabin Vaccine Institute, academic consortia, and large pharma companies with global health divisions (e.g., GSK). In the adjuvant supply market, it faces competition from large life science reagent companies (e.g., InvivoGen, Sigma-Aldrich) and specialized suppliers. Its focus on 'Serving the Underserved' helps differentiate it from purely commercial entities.